Search

Coloplast A-S (Class B)

Fechado

599.8 -1.96

Visão Geral

Variação de preço das ações

24h

Atual

Mín

595.8

Máximo

599.8

Indicadores-chave

By Trading Economics

Rendimento

-107M

805M

Vendas

28M

7B

P/E

Médio do Setor

33.124

77.256

EPS

4.67

Rendimento de Dividendos

3.78

Margem de lucro

11.569

Funcionários

16,814

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.78%

2.33%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-881M

136B

Abertura anterior

601.76

Fecho anterior

599.8

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de nov. de 2025, 21:06 UTC

Grandes Movimentos do Mercado

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 de nov. de 2025, 18:10 UTC

Ganhos

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8 de nov. de 2025, 13:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 de nov. de 2025, 12:00 UTC

Ganhos

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8 de nov. de 2025, 10:30 UTC

Ganhos

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8 de nov. de 2025, 03:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 de nov. de 2025, 03:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 de nov. de 2025, 03:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 de nov. de 2025, 22:36 UTC

Ganhos

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 de nov. de 2025, 22:22 UTC

Ganhos

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 de nov. de 2025, 22:03 UTC

Ganhos

Constellation Software 3Q Rev $2.95B >CSU.T

7 de nov. de 2025, 22:03 UTC

Ganhos

Constellation Software 3Q Net $210M >CSU.T

7 de nov. de 2025, 22:03 UTC

Ganhos

Constellation Software 3Q EPS $9.89 >CSU.T

7 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

7 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

7 de nov. de 2025, 20:59 UTC

Ganhos

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 de nov. de 2025, 20:26 UTC

Conversa de Mercado

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 de nov. de 2025, 20:22 UTC

Ganhos

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 de nov. de 2025, 20:04 UTC

Conversa de Mercado

Oil Futures Close Choppy Week With Losses -- Market Talk

7 de nov. de 2025, 19:34 UTC

Conversa de Mercado

Gold Posts Small Gain for Week -- Market Talk

7 de nov. de 2025, 19:31 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 de nov. de 2025, 19:17 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 de nov. de 2025, 19:09 UTC

Ganhos

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 de nov. de 2025, 19:08 UTC

Ganhos

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 de nov. de 2025, 18:31 UTC

Conversa de Mercado

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 de nov. de 2025, 17:27 UTC

Conversa de Mercado

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

7 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

4

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat